Beam Therapeutics (BEAM) SVP Bethany Cavanagh sells 6,198 shares

Rhea-AI Filing Summary

Bethany J. Cavanagh, SVP, Finance and Treasurer of Beam Therapeutics Inc., sold 6,198 shares of common stock on January 22, 2026 at a weighted average price of $35.0005 per share. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 19, 2025. After this transaction, she directly owns 34,813 shares of Beam Therapeutics common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cavanagh Bethany J

(Last) (First) (Middle)

C/O BEAM THERAPEUTICS INC.,

238 MAIN STREET

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Beam Therapeutics Inc. [ BEAM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Finance and Treasurer

3. Date of Earliest Transaction (Month/Day/Year)
01/22/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/22/2026		S(1)		6,198	D	$35.0005(2)	34,813	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares of Common Stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 19, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $35.00 to $35.015, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

	By: /s/ Christine Bellon, Attorney-in-fact	01/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many BEAM shares did Bethany J. Cavanagh sell on January 22, 2026?

On January 22, 2026, Bethany J. Cavanagh sold 6,198 shares of Beam Therapeutics Inc. common stock in an open market transaction.

What price did Bethany J. Cavanagh receive for the BEAM shares sold?

The sale was reported at a weighted average price of $35.0005 per share, with individual trades occurring between $35.00 and $35.015.

How many BEAM shares does Bethany J. Cavanagh own after this transaction?

Following the reported sale, Bethany J. Cavanagh beneficially owns 34,813 shares of Beam Therapeutics Inc. common stock directly.

Was the BEAM stock sale by Bethany J. Cavanagh made under a trading plan?

Yes. The shares were sold under a Rule 10b5-1 trading plan that Bethany J. Cavanagh adopted on September 19, 2025.

What is Bethany J. Cavanagh’s role at Beam Therapeutics Inc. (BEAM)?

Bethany J. Cavanagh is an officer of Beam Therapeutics Inc., serving as SVP, Finance and Treasurer.

Can investors obtain detailed trade prices for Bethany J. Cavanagh’s BEAM share sale?

Yes. She has undertaken to provide Beam Therapeutics Inc., any security holder, or SEC staff with full details of the number of shares sold at each price within the reported range upon request.